Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.